You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 1 - 10 of 3594 results
  1. IND Enabling Non-Clinical Development of E1v1.11, a Morpholino Anti-Sense Oligonucleotide for the treatment of Spinal Muscular Atrophy.

    SBC: Shift Pharmaceuticals Holdings, Inc.            Topic: 106

    Abstract: The objective of this project is to perform the required (and previously approved) IND-enabling experimental work for E1v1.11, a novel drug candidate for Spinal Muscular Atrophy (SMA). SMA is an autosomal recessive disorder that is the leading genetic cause of infantile death worldwide, occurring in ~1:10,000 live births. The gene responsible for SMA is called survival motor neuron-1 (SM ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. A Novel Synthetic Biology-Derived Microbiome Therapeutic to Treat Viral-Induced Acute Respiratory Distress Syndrome (ARDS)

    SBC: Rise Therapeutics, LLC            Topic: NIAID

    PROJECT SUMMARY Acute respiratory distress syndrome (ARDS) is a severe life-threatening complication that can be caused by viral infection. The disease is characterized by cytokine-driven hyperinflammation and leukocytes count changes. The innate immune response has been linked to ARDS immunopathogenesis. In this regard, neutrophils have been highlighted as essential effector cells in the developm ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Class II Human Leukocyte Antigen biologics for antibody-mediated graft rejection.

    SBC: Antiger Therapeutics Inc.            Topic: NIAID

    PROJECT SUMMARY/ABSTRACT The mission of Antiger Therapeutics Inc. is to develop novel immunotherapies for transplant recipients to improve long-term graft outcomes and minimize adverse effects. Antibody-mediated rejection (AMR) is a leading cause of graft loss, with over 3000 new cases per year in the United States and estimated market size of $90 million. However, this estimate is likely to under ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. ErythroMer: Nanoscale BioSynthetic Red Cell Substitute

    SBC: KaloCyte Inc            Topic: NHLBI

    Research Summary/Abstract ErythroMer (EM) is a novel biosynthetic blood substitute developed to address the critically unmet need for emergency transfusion in situations where the use of banked red blood cells (RBCs) are either not available or undesirable. EM is a self-assembled lipid-oligomeric hybrid nanoparticle with a high per particle payload of hemoglobin (Hb) and the allosteric modifier, R ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Validation and Improvement of ISPRI-HCP: An Innovative Platform for Immunogenicity Risk Assessment of Process-related Protein Impurities

    SBC: EPIVAX, INC.            Topic: NIAID

    ABSTRACT The identification and removal of process-related protein impurities (PRPI) from biologic products is a critical step in drug development. Despite recent improvements in the purification and processing of biologics, the presence of immunogenic PRPI continue to raise concerns about drug safety and efficacy. We propose an innovative approach for assessing immunogenicity risk of PRPI using o ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Evaluation of a mobile app-based video Directly Observed Therapy (video DOT) intervention for medication adherence in pediatric heart transplant patients

    SBC: EMOCHA MOBILE HEALTH INC.            Topic: NHLBI

    Few interventions have proven to be successful in promoting medication adherence and impacting short- and long-term posttransplant outcomes in adolescent heart transplant (HT) recipients. Improving adherence is a persistent challenge with youth experiencing chronic health conditions, especially among adolescent transplant recipients. Adolescent organ transplant recipients experience unique challen ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. A genetically modified Plasmodium falciparum sporozoite vaccine attenuated at the late-liver stage

    SBC: SANARIA INC.            Topic: NIAID

    ABSTRACT In 2020 malaria caused 241M clinical cases and 627,000 deaths, the greatest numbers of annual deaths since 2012. There were more deaths in Africa from malaria than from COVID-19. There is an urgent unmet medical need for a malaria vaccine that prevents infection and disease in individuals and can be deployed in mass vaccination programs for malaria elimination. The RTS,S malaria vaccine w ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. FimH-Targeting Antibody-Recruiting Molecules as Novel Drugs for Preventing Complicated Urinary Tract Infections

    SBC: FIMBRION THERAPEUTICS INC            Topic: NIAID

    1 ABSTRACT. Urinary tract infections (UTI) are extremely common world-wide, and can lead to serious2 complications, including renal scarring and urosepsis. Standard-of-care treatments rely on antibiotics: empiric3 treatment for uncomplicated UTI (uUTI), broad-spectrum for complicated UTI (cUTI), and long-term prophylaxis4 for recurrent UTI (rUTI). This constant antibiotic exposure not only disrupt ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Progressing PfSPZ vaccines for malaria to licensure and commercialization

    SBC: SANARIA INC.            Topic: NIAID

    ABSTRACT Sanaria’s mission is the licensure and marketing of Plasmodium falciparum (Pf) sporozoite (SPZ) vaccines against malaria that will prevent malaria infection and transmission in individuals and can be used in public health-driven malaria control and elimination programs. The aim of this proposal is to shorten the time to licensure and marketing of Sanaria’s PfSPZ vaccines by funding as ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Recombinant human CC10 protein for treatment and prevention of chronic lung allograft dysfunction

    SBC: APC BIO INNOVATIONS INC            Topic: NHLBI

    Abstract Over 5,000 lung transplants (LTx) are performed in the US each year to save the lives of patients in respiratory failure due to COPD, idiopathic pulmonary fibrosis, cystic fibrosis, pulmonary hypertension, and other terminal lung conditions. The vast majority of LTx, long-term survival is significantly limited by chronic lung allograft dysfunction (CLAD) with a median survival of 6 years ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government